Ids stringlengths 36 36 | text stringlengths 45 2.03k | label int64 0 1 |
|---|---|---|
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Confusional state 1/32 (3.13%) secondary trial: Cardiac failure congestive 1/752 (0.13%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Confusional state 1/32 (3.13%) secondary trial: Left ventricular dysfunction 0/752 (0.00%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Confusional state 1/32 (3.13%) secondary trial: Total: 117/382 (30.63%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Confusional state 1/32 (3.13%) secondary trial: Anaemia 3/382 (0.79%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Confusional state 1/32 (3.13%) secondary trial: Disseminated intravascular coagulation 0/382 (0.00%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Confusional state 1/32 (3.13%) secondary trial: Febrile neutropenia 11/382 (2.88%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Confusional state 1/32 (3.13%) secondary trial: Neutropenia 20/382 (5.24%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Confusional state 1/32 (3.13%) secondary trial: Thrombocytopenia 0/382 (0.00%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Confusional state 1/32 (3.13%) secondary trial: Atrial fibrillation 1/382 (0.26%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Confusional state 1/32 (3.13%) secondary trial: Atrial flutter 1/382 (0.26%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Confusional state 1/32 (3.13%) secondary trial: Cardiac failure congestive 0/382 (0.00%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Confusional state 1/32 (3.13%) secondary trial: Left ventricular dysfunction 1/382 (0.26%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
20c35c89-8d23-4be3-b603-ac0ee0f3b4de | Patients with histologic confirmation of invasive breast carcinoma. Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T1 N1 M1) are eligible for the primary trial. | 0 |
20c35c89-8d23-4be3-b603-ac0ee0f3b4de | Patients must have intact primary tumor. Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T1 N1 M1) are eligible for the primary trial. | 0 |
20c35c89-8d23-4be3-b603-ac0ee0f3b4de | Patients greater than or equal to 18 years. Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T1 N1 M1) are eligible for the primary trial. | 0 |
20c35c89-8d23-4be3-b603-ac0ee0f3b4de | Patients should have T1N1-3M0 or T2-4 N0-3M0. Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T1 N1 M1) are eligible for the primary trial. | 0 |
20c35c89-8d23-4be3-b603-ac0ee0f3b4de | Patients with bilateral breast cancer are eligible. Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T1 N1 M1) are eligible for the primary trial. | 0 |
20c35c89-8d23-4be3-b603-ac0ee0f3b4de | Patients with second primary breast cancers are eligible. Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T1 N1 M1) are eligible for the primary trial. | 0 |
20c35c89-8d23-4be3-b603-ac0ee0f3b4de | Patients should have a Karnofsky performance scale of greater than or equal to 70%. Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T1 N1 M1) are eligible for the primary trial. | 0 |
20c35c89-8d23-4be3-b603-ac0ee0f3b4de | Patients must have clinically measurable disease to be treated in the neoadjuvant setting. Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T1 N1 M1) are eligible for the primary trial. | 0 |
20c35c89-8d23-4be3-b603-ac0ee0f3b4de | Patients should have adequate bone marrow function, as defined by peripheral granulocyte count of greater than or equal to 1500/mm^3, and platelet count greater than or equal to 100000mm^3. Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T1 N1 M1) are eligible for the primary trial. | 0 |
20c35c89-8d23-4be3-b603-ac0ee0f3b4de | Patients must have adequate liver function with a bilirubin within normal laboratory values. Alkaline phosphatase and transaminases (ALT and AST) may be up to 1.5 x upper limit of normal (ULN) of the institution. Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T1 N1 M1) are eligible ... | 0 |
20c35c89-8d23-4be3-b603-ac0ee0f3b4de | Patients should have adequate renal function with creatinine levels within normal range. Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T1 N1 M1) are eligible for the primary trial. | 0 |
20c35c89-8d23-4be3-b603-ac0ee0f3b4de | Patients should have a normal left ventricular ejection fraction (LVEF) of greater than or equal to 50%. Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T1 N1 M1) are eligible for the primary trial. | 0 |
20c35c89-8d23-4be3-b603-ac0ee0f3b4de | Negative serum or urine pregnancy test for a woman of childbearing potential (WOCBP). Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T1 N1 M1) are eligible for the primary trial. | 0 |
20c35c89-8d23-4be3-b603-ac0ee0f3b4de | WOCBP must use a reliable and appropriate contraceptive method during the study and six months after chemotherapy is completed. WOCBP are women who are not menopausal for 12 months or had no previous surgical sterilization. Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T1 N1 M1) ar... | 0 |
20c35c89-8d23-4be3-b603-ac0ee0f3b4de | Patients must agree to have study biopsies. Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T1 N1 M1) are eligible for the primary trial. | 0 |
20c35c89-8d23-4be3-b603-ac0ee0f3b4de | Patients must sign an informed consent indicating that they are aware of the investigational nature of the study, in keeping with institutional policy. Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T1 N1 M1) are eligible for the primary trial. | 0 |
20c35c89-8d23-4be3-b603-ac0ee0f3b4de | Patients with a history of other invasive malignancies diagnosed and treated within the previous 5 years, except non-melanoma skin cancer and non-invasive cervical cancer. Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T1 N1 M1) are eligible for the primary trial. | 0 |
20c35c89-8d23-4be3-b603-ac0ee0f3b4de | Her2Neu, ER and PR positive patients should be excluded. Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T1 N1 M1) are eligible for the primary trial. | 0 |
20c35c89-8d23-4be3-b603-ac0ee0f3b4de | Patients with Inflammatory breast cancer (IBC) are excluded. Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T1 N1 M1) are eligible for the primary trial. | 0 |
20c35c89-8d23-4be3-b603-ac0ee0f3b4de | Patients with an organ allograft or other history of immune compromise. Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T1 N1 M1) are eligible for the primary trial. | 0 |
20c35c89-8d23-4be3-b603-ac0ee0f3b4de | Prior treatment with any investigational drug within the preceding 4 weeks. Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T1 N1 M1) are eligible for the primary trial. | 0 |
20c35c89-8d23-4be3-b603-ac0ee0f3b4de | Chronic treatment with systemic steroids or another immunosuppressive agent. Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T1 N1 M1) are eligible for the primary trial. | 0 |
20c35c89-8d23-4be3-b603-ac0ee0f3b4de | A Known history of HIV seropositivity. Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T1 N1 M1) are eligible for the primary trial. | 0 |
20c35c89-8d23-4be3-b603-ac0ee0f3b4de | Patients with an active, bleeding diathesis or on oral anti-vitamin K medication (except low dose coumarin defined as 1 mg a day). Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T1 N1 M1) are eligible for the primary trial. | 0 |
20c35c89-8d23-4be3-b603-ac0ee0f3b4de | Other concurrent and/or uncontrolled medical disease which could compromise participation in the study (i.e., uncontrolled diabetes, uncontrolled hypertension, severe infection, severe malnutrition, unstable angina, or congestive heart failure - New York Heart Association Class III or IV, ventricular arrhythmias, activ... | 0 |
20c35c89-8d23-4be3-b603-ac0ee0f3b4de | Patients with a pre-existing peripheral neuropathy. Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T1 N1 M1) are eligible for the primary trial. | 0 |
f17cb242-419d-4f5d-bfa4-41494ed5ac0e | primary trial: Laser Therapy Alone secondary trial: Part A Abemaciclib: HR+, HER2+ Breast Cancer Laser Therapy is in each cohort of the primary trial and the secondary trial, along with neoadjuvant chemotherapy. | 0 |
f17cb242-419d-4f5d-bfa4-41494ed5ac0e | primary trial: Laser Therapy Alone secondary trial: Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET). Participants with hormone receptor positive HR+, HER2+ breast cancer receiving concurrent t... | 0 |
f17cb242-419d-4f5d-bfa4-41494ed5ac0e | primary trial: Laser Therapy Alone secondary trial: Part B Abemaciclib: HR+, HER2- Breast Cancer Laser Therapy is in each cohort of the primary trial and the secondary trial, along with neoadjuvant chemotherapy. | 0 |
f17cb242-419d-4f5d-bfa4-41494ed5ac0e | primary trial: Laser Therapy Alone secondary trial: Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for in combination with endocrine therapy (ET). Laser Therapy is in each cohort of the primary trial and the secondary trial, along wit... | 0 |
f17cb242-419d-4f5d-bfa4-41494ed5ac0e | primary trial: Laser Therapy Alone secondary trial: Participants may continue to receive treatment until discontinuation criteria are met. Laser Therapy is in each cohort of the primary trial and the secondary trial, along with neoadjuvant chemotherapy. | 0 |
f17cb242-419d-4f5d-bfa4-41494ed5ac0e | primary trial: therapist administered laser treatment secondary trial: Part A Abemaciclib: HR+, HER2+ Breast Cancer Laser Therapy is in each cohort of the primary trial and the secondary trial, along with neoadjuvant chemotherapy. | 0 |
f17cb242-419d-4f5d-bfa4-41494ed5ac0e | primary trial: therapist administered laser treatment secondary trial: Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET). Participants with hormone receptor positive HR+, HER2+ breast cancer rec... | 0 |
f17cb242-419d-4f5d-bfa4-41494ed5ac0e | primary trial: therapist administered laser treatment secondary trial: Part B Abemaciclib: HR+, HER2- Breast Cancer Laser Therapy is in each cohort of the primary trial and the secondary trial, along with neoadjuvant chemotherapy. | 0 |
f17cb242-419d-4f5d-bfa4-41494ed5ac0e | primary trial: therapist administered laser treatment secondary trial: Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for in combination with endocrine therapy (ET). Laser Therapy is in each cohort of the primary trial and the seconda... | 0 |
f17cb242-419d-4f5d-bfa4-41494ed5ac0e | primary trial: therapist administered laser treatment secondary trial: Participants may continue to receive treatment until discontinuation criteria are met. Laser Therapy is in each cohort of the primary trial and the secondary trial, along with neoadjuvant chemotherapy. | 0 |
f17cb242-419d-4f5d-bfa4-41494ed5ac0e | primary trial: laser: therapist administered laser secondary trial: Part A Abemaciclib: HR+, HER2+ Breast Cancer Laser Therapy is in each cohort of the primary trial and the secondary trial, along with neoadjuvant chemotherapy. | 0 |
f17cb242-419d-4f5d-bfa4-41494ed5ac0e | primary trial: laser: therapist administered laser secondary trial: Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET). Participants with hormone receptor positive HR+, HER2+ breast cancer receiv... | 0 |
f17cb242-419d-4f5d-bfa4-41494ed5ac0e | primary trial: laser: therapist administered laser secondary trial: Part B Abemaciclib: HR+, HER2- Breast Cancer Laser Therapy is in each cohort of the primary trial and the secondary trial, along with neoadjuvant chemotherapy. | 0 |
f17cb242-419d-4f5d-bfa4-41494ed5ac0e | primary trial: laser: therapist administered laser secondary trial: Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for in combination with endocrine therapy (ET). Laser Therapy is in each cohort of the primary trial and the secondary ... | 0 |
f17cb242-419d-4f5d-bfa4-41494ed5ac0e | primary trial: laser: therapist administered laser secondary trial: Participants may continue to receive treatment until discontinuation criteria are met. Laser Therapy is in each cohort of the primary trial and the secondary trial, along with neoadjuvant chemotherapy. | 0 |
f17cb242-419d-4f5d-bfa4-41494ed5ac0e | primary trial: Mld Alone secondary trial: Part A Abemaciclib: HR+, HER2+ Breast Cancer Laser Therapy is in each cohort of the primary trial and the secondary trial, along with neoadjuvant chemotherapy. | 0 |
f17cb242-419d-4f5d-bfa4-41494ed5ac0e | primary trial: Mld Alone secondary trial: Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET). Participants with hormone receptor positive HR+, HER2+ breast cancer receiving concurrent trastuzumab... | 0 |
f17cb242-419d-4f5d-bfa4-41494ed5ac0e | primary trial: Mld Alone secondary trial: Part B Abemaciclib: HR+, HER2- Breast Cancer Laser Therapy is in each cohort of the primary trial and the secondary trial, along with neoadjuvant chemotherapy. | 0 |
f17cb242-419d-4f5d-bfa4-41494ed5ac0e | primary trial: Mld Alone secondary trial: Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for in combination with endocrine therapy (ET). Laser Therapy is in each cohort of the primary trial and the secondary trial, along with neoadjuv... | 0 |
f17cb242-419d-4f5d-bfa4-41494ed5ac0e | primary trial: Mld Alone secondary trial: Participants may continue to receive treatment until discontinuation criteria are met. Laser Therapy is in each cohort of the primary trial and the secondary trial, along with neoadjuvant chemotherapy. | 0 |
f17cb242-419d-4f5d-bfa4-41494ed5ac0e | primary trial: therapist administered manual lymphatic drainage secondary trial: Part A Abemaciclib: HR+, HER2+ Breast Cancer Laser Therapy is in each cohort of the primary trial and the secondary trial, along with neoadjuvant chemotherapy. | 0 |
f17cb242-419d-4f5d-bfa4-41494ed5ac0e | primary trial: therapist administered manual lymphatic drainage secondary trial: Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET). Participants with hormone receptor positive HR+, HER2+ breast ... | 0 |
f17cb242-419d-4f5d-bfa4-41494ed5ac0e | primary trial: therapist administered manual lymphatic drainage secondary trial: Part B Abemaciclib: HR+, HER2- Breast Cancer Laser Therapy is in each cohort of the primary trial and the secondary trial, along with neoadjuvant chemotherapy. | 0 |
f17cb242-419d-4f5d-bfa4-41494ed5ac0e | primary trial: therapist administered manual lymphatic drainage secondary trial: Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for in combination with endocrine therapy (ET). Laser Therapy is in each cohort of the primary trial and t... | 0 |
f17cb242-419d-4f5d-bfa4-41494ed5ac0e | primary trial: therapist administered manual lymphatic drainage secondary trial: Participants may continue to receive treatment until discontinuation criteria are met. Laser Therapy is in each cohort of the primary trial and the secondary trial, along with neoadjuvant chemotherapy. | 0 |
f17cb242-419d-4f5d-bfa4-41494ed5ac0e | primary trial: manual lymphatic drainage: therapist administered massage therapy secondary trial: Part A Abemaciclib: HR+, HER2+ Breast Cancer Laser Therapy is in each cohort of the primary trial and the secondary trial, along with neoadjuvant chemotherapy. | 0 |
f17cb242-419d-4f5d-bfa4-41494ed5ac0e | primary trial: manual lymphatic drainage: therapist administered massage therapy secondary trial: Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET). Participants with hormone receptor positive H... | 0 |
f17cb242-419d-4f5d-bfa4-41494ed5ac0e | primary trial: manual lymphatic drainage: therapist administered massage therapy secondary trial: Part B Abemaciclib: HR+, HER2- Breast Cancer Laser Therapy is in each cohort of the primary trial and the secondary trial, along with neoadjuvant chemotherapy. | 0 |
f17cb242-419d-4f5d-bfa4-41494ed5ac0e | primary trial: manual lymphatic drainage: therapist administered massage therapy secondary trial: Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for in combination with endocrine therapy (ET). Laser Therapy is in each cohort of the pr... | 0 |
f17cb242-419d-4f5d-bfa4-41494ed5ac0e | primary trial: manual lymphatic drainage: therapist administered massage therapy secondary trial: Participants may continue to receive treatment until discontinuation criteria are met. Laser Therapy is in each cohort of the primary trial and the secondary trial, along with neoadjuvant chemotherapy. | 0 |
fc5c4554-7ce9-4c16-b374-a3cd9d15b021 | primary trial: Subjects who were confirmed to have a response after receiving at least two courses of weekly paclitaxel therapy and considered to need to continue the therapy by the investigator/subinvestigator among the patients with advanced or recurrent breast cancer who had met the selection criteria and participat... | 0 |
fc5c4554-7ce9-4c16-b374-a3cd9d15b021 | primary trial: Subjects who were confirmed to have a response after receiving at least two courses of weekly paclitaxel therapy and considered to need to continue the therapy by the investigator/subinvestigator among the patients with advanced or recurrent breast cancer who had met the selection criteria and participat... | 0 |
fc5c4554-7ce9-4c16-b374-a3cd9d15b021 | primary trial: Subjects who were confirmed to have a response after receiving at least two courses of weekly paclitaxel therapy and considered to need to continue the therapy by the investigator/subinvestigator among the patients with advanced or recurrent breast cancer who had met the selection criteria and participat... | 0 |
fc5c4554-7ce9-4c16-b374-a3cd9d15b021 | primary trial: Subjects who were confirmed to have a response after receiving at least two courses of weekly paclitaxel therapy and considered to need to continue the therapy by the investigator/subinvestigator among the patients with advanced or recurrent breast cancer who had met the selection criteria and participat... | 0 |
fc5c4554-7ce9-4c16-b374-a3cd9d15b021 | primary trial: Subjects who were confirmed to have a response after receiving at least two courses of weekly paclitaxel therapy and considered to need to continue the therapy by the investigator/subinvestigator among the patients with advanced or recurrent breast cancer who had met the selection criteria and participat... | 0 |
fc5c4554-7ce9-4c16-b374-a3cd9d15b021 | primary trial: Subjects who were confirmed to have a response after receiving at least two courses of weekly paclitaxel therapy and considered to need to continue the therapy by the investigator/subinvestigator among the patients with advanced or recurrent breast cancer who had met the selection criteria and participat... | 0 |
fc5c4554-7ce9-4c16-b374-a3cd9d15b021 | primary trial: Subjects who were confirmed to have a response after receiving at least two courses of weekly paclitaxel therapy and considered to need to continue the therapy by the investigator/subinvestigator among the patients with advanced or recurrent breast cancer who had met the selection criteria and participat... | 0 |
fc5c4554-7ce9-4c16-b374-a3cd9d15b021 | primary trial: Subjects who were confirmed to have a response after receiving at least two courses of weekly paclitaxel therapy and considered to need to continue the therapy by the investigator/subinvestigator among the patients with advanced or recurrent breast cancer who had met the selection criteria and participat... | 0 |
fc5c4554-7ce9-4c16-b374-a3cd9d15b021 | primary trial: Subjects who were confirmed to have a response after receiving at least two courses of weekly paclitaxel therapy and considered to need to continue the therapy by the investigator/subinvestigator among the patients with advanced or recurrent breast cancer who had met the selection criteria and participat... | 0 |
fc5c4554-7ce9-4c16-b374-a3cd9d15b021 | primary trial: Subjects who were confirmed to have a response after receiving at least two courses of weekly paclitaxel therapy and considered to need to continue the therapy by the investigator/subinvestigator among the patients with advanced or recurrent breast cancer who had met the selection criteria and participat... | 0 |
fc5c4554-7ce9-4c16-b374-a3cd9d15b021 | primary trial: Subjects who were confirmed to have a response after receiving at least two courses of weekly paclitaxel therapy and considered to need to continue the therapy by the investigator/subinvestigator among the patients with advanced or recurrent breast cancer who had met the selection criteria and participat... | 0 |
fc5c4554-7ce9-4c16-b374-a3cd9d15b021 | primary trial: Subjects who were confirmed to have a response after receiving at least two courses of weekly paclitaxel therapy and considered to need to continue the therapy by the investigator/subinvestigator among the patients with advanced or recurrent breast cancer who had met the selection criteria and participat... | 0 |
fc5c4554-7ce9-4c16-b374-a3cd9d15b021 | primary trial: Subjects who were confirmed to have a response after receiving at least two courses of weekly paclitaxel therapy and considered to need to continue the therapy by the investigator/subinvestigator among the patients with advanced or recurrent breast cancer who had met the selection criteria and participat... | 0 |
fc5c4554-7ce9-4c16-b374-a3cd9d15b021 | primary trial: Subjects who were confirmed to have a response after receiving at least two courses of weekly paclitaxel therapy and considered to need to continue the therapy by the investigator/subinvestigator among the patients with advanced or recurrent breast cancer who had met the selection criteria and participat... | 0 |
fc5c4554-7ce9-4c16-b374-a3cd9d15b021 | primary trial: Subjects who were confirmed to have a response after receiving at least two courses of weekly paclitaxel therapy and considered to need to continue the therapy by the investigator/subinvestigator among the patients with advanced or recurrent breast cancer who had met the selection criteria and participat... | 0 |
fc5c4554-7ce9-4c16-b374-a3cd9d15b021 | primary trial: Subjects who were confirmed to have a response after receiving at least two courses of weekly paclitaxel therapy and considered to need to continue the therapy by the investigator/subinvestigator among the patients with advanced or recurrent breast cancer who had met the selection criteria and participat... | 0 |
fc5c4554-7ce9-4c16-b374-a3cd9d15b021 | primary trial: Subjects who were confirmed to have a response after receiving at least two courses of weekly paclitaxel therapy and considered to need to continue the therapy by the investigator/subinvestigator among the patients with advanced or recurrent breast cancer who had met the selection criteria and participat... | 0 |
fc5c4554-7ce9-4c16-b374-a3cd9d15b021 | primary trial: Subjects who were confirmed to have a response after receiving at least two courses of weekly paclitaxel therapy and considered to need to continue the therapy by the investigator/subinvestigator among the patients with advanced or recurrent breast cancer who had met the selection criteria and participat... | 0 |
fc5c4554-7ce9-4c16-b374-a3cd9d15b021 | primary trial: Subjects who were confirmed to have a response after receiving at least two courses of weekly paclitaxel therapy and considered to need to continue the therapy by the investigator/subinvestigator among the patients with advanced or recurrent breast cancer who had met the selection criteria and participat... | 0 |
fc5c4554-7ce9-4c16-b374-a3cd9d15b021 | primary trial: Subjects who were confirmed to have a response after receiving at least two courses of weekly paclitaxel therapy and considered to need to continue the therapy by the investigator/subinvestigator among the patients with advanced or recurrent breast cancer who had met the selection criteria and participat... | 0 |
fc5c4554-7ce9-4c16-b374-a3cd9d15b021 | primary trial: Subjects who were confirmed to have a response after receiving at least two courses of weekly paclitaxel therapy and considered to need to continue the therapy by the investigator/subinvestigator among the patients with advanced or recurrent breast cancer who had met the selection criteria and participat... | 0 |
fc5c4554-7ce9-4c16-b374-a3cd9d15b021 | primary trial: Subjects who were confirmed to have a response after receiving at least two courses of weekly paclitaxel therapy and considered to need to continue the therapy by the investigator/subinvestigator among the patients with advanced or recurrent breast cancer who had met the selection criteria and participat... | 0 |
fc5c4554-7ce9-4c16-b374-a3cd9d15b021 | primary trial: Subjects who were confirmed to have a response after receiving at least two courses of weekly paclitaxel therapy and considered to need to continue the therapy by the investigator/subinvestigator among the patients with advanced or recurrent breast cancer who had met the selection criteria and participat... | 0 |
96b77cdd-aa9f-4770-8447-8a04d9ca5da7 | Clinical stage I or II (T1 or T2, N0 or N1) invasive mammary carcinoma Patients with Clinical stage II (T2 N1) invasive mammary carcinoma are not eligible for the primary trial. | 0 |
96b77cdd-aa9f-4770-8447-8a04d9ca5da7 | Diagnosis may be made by fine needle aspiration cytology or core biopsy Patients with Clinical stage II (T2 N1) invasive mammary carcinoma are not eligible for the primary trial. | 0 |
96b77cdd-aa9f-4770-8447-8a04d9ca5da7 | A repeat core biopsy is not required for patients who have a paraffin embedded diagnostic core biopsy specimen available for immunohistochemical staining Patients with Clinical stage II (T2 N1) invasive mammary carcinoma are not eligible for the primary trial. | 0 |
96b77cdd-aa9f-4770-8447-8a04d9ca5da7 | Patients with locally advanced disease who are planning to undergo preoperative neoadjuvant therapy are not eligible* Patients with Clinical stage II (T2 N1) invasive mammary carcinoma are not eligible for the primary trial. | 0 |
96b77cdd-aa9f-4770-8447-8a04d9ca5da7 | Locally advanced disease includes any of the following: Patients with Clinical stage II (T2 N1) invasive mammary carcinoma are not eligible for the primary trial. | 0 |
96b77cdd-aa9f-4770-8447-8a04d9ca5da7 | Primary tumor 5 cm (T3) Patients with Clinical stage II (T2 N1) invasive mammary carcinoma are not eligible for the primary trial. | 0 |
96b77cdd-aa9f-4770-8447-8a04d9ca5da7 | Tumor of any size with direct extension to the chest wall or skin (T4a-c) Patients with Clinical stage II (T2 N1) invasive mammary carcinoma are not eligible for the primary trial. | 0 |
96b77cdd-aa9f-4770-8447-8a04d9ca5da7 | Inflammatory breast cancer (T4d) Patients with Clinical stage II (T2 N1) invasive mammary carcinoma are not eligible for the primary trial. | 0 |
96b77cdd-aa9f-4770-8447-8a04d9ca5da7 | Fixed axillary lymph node metastases (N2) Patients with Clinical stage II (T2 N1) invasive mammary carcinoma are not eligible for the primary trial. | 0 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.